Kyle Baron joined MetrumRG in 2010 as a Research Scientist, working with the systems biology group to develop Bayesian hepatitis C viral dymanic models to help quantify antiviral drug effects and predict long-term viral response rates.
Kyle T. Baron and Marc R. Gastonguay. Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve. ACoP 6. October 2015.
RJ Eudy, MR Gastonguay, KT Baron, and MM Riggs.Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model. CPT Pharmacometrics Syst. Pharmacol. 2015 Sep; 4(9): 527-536.
Eudy RJ, Gastonguay MR, Baron KT, Riggs MM. Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis. PAGE 24 (2015) Abstr 3355
J. S. Gewandter, R. H. Dworkin, D. C. Turk, M. P. McDermott, R. Baron, M. R. Gastonguay, I. Gilron, N. P. Katz, C. Mehta, S. N. Raja, S. Senn, C. Taylor, P. Cowan, P. Desjardins, R. Dimitrova, R. Dionne, J. T. Farrar, D. J. Hewitt, S. Iyengar, G. W. Jay, E. Kalso, R. D. Kerns, R. Leff, M. Leong, K. L. Petersen, B. M. Ravina, C. Rauschkolb, A. S. C. Rice, M. C. Rowbotham, C. Sampaio, S. H. Sindrup, J. W. Stauffer, I. Steigerwald, J. Stewart, J. Tobias, R.-D. Treede, M. Wallace, and R. E. White. Research designs for proof-of-concept chronic pain clinical trials: Immpact recommendations. Pain, May 2014.
An Evaluation of Calcilytic Effects on Parathyroid Hormone and Bone Mineral Density Response Using a Physiologically-Based, Multiscale Systems Pharmacology Model. Kyle T. Baron, Matthew M. Riggs, Ryoko Sawamura, Takako Shimizu, Fumihiko Okada, Jin Zhou, Takahiro Shibayama, Mendel Jansen. Published at ASBMR in October, 2013.
S. Olson, K. Baron, M. Riggs, W. O. Böcher, and F. J. Mensa. 1212 pharmacokinetic modelling of the relationship between sustained virological response and plasma concentrations of faldaprevir or bi-207127 in hcv gt1-infected patients in sound-c2. Journal of Hepatology, 58:S492–S493.
Matthew M. Riggs, Kyle T. Baron, Elodie L. Plan, Marc R. Gastonguay. Qualification of a Physiologically-Based Model for Predicted Bone Marker and Bone Mineral Density Changes Associated with Denosumab Treatment. Presented at American Society of Bone Mineral Research (ASBMR) Annual Meeting, Minneapolis, MN; October 14, 2012 (Abstract# SU0363).
Malaz AbuTarif, Stephen Kaplita, Robert M. Berman, Vlad Coric, Kyle Baron. Avagacestat (BMS-708163) Exposures and Study Discontinuations in Patients With Mild-to-Moderate Alzheimer’s Disease. AAIC meeting, July 2012, Vancouver, BC.
Elodie L. Plan, Kyle T. Baron, Marc R. Gastonguay, Jonathan L. French, William R. Gillespie, and Matthew M. Riggs. Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension. PAGE 21 (2012) Abstr 2592.
Kyle T. Baron, Patanjali Ravva, Vivek Purohit, Matthew M. Riggs, Marc R. Gastonguay. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 2011.
Polhamus, D, Baron KT, Purohit, VS, Ravva P, Rogers, JA, Gastonguay MR. A Time to Event Approach for Standard of Care Meta-Analysis in HCV Trials. Presented at ACOP 2011, San Diego, CA
Baron K, Ravva P, Purohit V, Riggs MM, Gastonguay MR. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. Presented at ACOP 2011, San Diego, CA.